TrialProstate cancer and prostatic diseases2026

Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.

Alberto Dalla Volta et al.PubMed ↗Publisher ↗

No numbers read from the abstract.